The prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.
This meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.
A comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, namely, overall survival (OS), and the second endpoint was short-term survival, including progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS).
A total of 21 studies, with 2413 patients, were included in this meta-analysis. Elevated sPD-L1 was associated with worse OS [HR = 2.46, 95% confidence interval (CI) 1.74-3.49, P &lt;0.001]. Moreover, high sPD-L1 was predictive of worse PFS/DFS/RFS/CSS (HR = 2.22, 95% CI 1.47-3.35, P &lt;0.001). High sPD-L1 was consistently correlated with poor OS and PFS/DFS/RFS/CSS irrespective of study design, sample, and cut-off value of sPD-L1. However, there was non-significant correlation between sPD-L1 and sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status, tumor differentiation, or serum lactate dehydrogenase.
This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments.
This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. https://www.selleckchem.com/products/mi-3-menin-mll-inhibitor.html In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments.Brain cancer is a disease caused by the growth of abnormal aggressive cells in the brain outside of normal cells. Symptoms and diagnosis of brain cancer cases are producing more accurate results day by day in parallel with the development of technological opportunities. In this study, a deep learning model called BrainMRNet which is developed for mass detection in open-source brain magnetic resonance images was used. The BrainMRNet model includes three processing steps attention modules, the hypercolumn technique, and residual blocks. To demonstrate the accuracy of the proposed model, three types of tumor data leading to brain cancer were examined in this study glioma, meningioma, and pituitary. In addition, a segmentation method was proposed, which additionally determines in which lobe area of the brain the two classes of tumors that cause brain cancer are more concentrated. The classification accuracy rates were performed in the study; it was 98.18% in glioma tumor, 96.73% in meningioma tumor, and 98.18% in pituitary tumor. At the end of the experiment, using the subset of glioma and meningioma tumor images, it was determined which at brain lobe the tumor region was seen, and 100% success was achieved in the analysis of this determination. In this study, a hybrid deep learning model is presented to determine the detection of the brain tumor. In addition, open-source software was proposed, which statistically found in which lobe region of the human brain the brain tumor occurred. The methods applied and tested in the experiments have shown promising results with a high level of accuracy, precision, and specificity. These results demonstrate the availability of the proposed approach in clinical settings to support the medical decision regarding brain tumor detection.The risk factors and clinical characteristics of ICI-induced immune-mediated hepatotoxicity (IMH) are not fully understood. Thus, the present study sought to clarify the clinical features of IMH.
All patients treated with ICIs between September 2014 and April 2019 at our institution were included. Clinical data were retrospectively collected from medical records. The frequency of grade???2 liver damage, clinical characteristics, and risk factors for developing IMH were examined.
Overall, 250 patients (median age 71years; range 30-87years; 202 males and 48 females) were included in the analyses. Forty-five patients had elevated transaminase levels (&gt;?threefold the upper limit of normal). Of these, 21 were considered to have IMH. The remaining 24 patients had other causes of elevated transaminase levels. Steroids were administered to 13/21 patients with IMH. Although all patients exhibited improvement, IMH was not associated with the anticancer efficacy of the ICIs or OS. A multivariable analysis reveaatients with malignant melanoma and in patients given ipilimumab-nivolumab combination therapy.To compare the efficacy and safety of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IVC) against intravesical BCG immunotherapy in high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of the bladder tumor (TURBT).
130 patients with high-risk NMIBC who had underwent TURBT were divided into two groups, of which IAC?+?IVC group received four courses of IAC (cisplatin and epirubicin) combined with IVC (epirubicin or pirarubicin) after surgery and BCG group received intravesical BCG immunotherapy. Recurrence rate and progression rate were assessed by Chi-square test, while recurrence-free survival and progression-free survival were calculated using the Kaplan-Meier method.
In this study, the recurrence rate was 27.9% (12/43) in IAC?+?IVC group and 26.4% (14/53) in BCG group, while progression rate was 9.3% (4/43) in IAC?+?IVC group and 9.4% (5/53) in BCG group. Both of the recurrence and progression rate did not show a significant difference. In the Kaplan-Meier plot, no difference was found with respect to recurrence-free survival and progression-free survival. Moreover, 46.5% (20/43) patients suffered from adverse events of IAC and 83.1% (49/59) patients suffered from adverse events associated with BCG, of which 6 patients discontinued treatment due to serious adverse events of BCG. Univariate analysis suggested that only recurrent tumor could be an independent risk factor related to recurrence.
IAC combined with IVC used in high-risk NMIBC could reduce the recurrence and progression as effective as BCG instillation with lower adverse events.
IAC combined with IVC used in high-risk NMIBC could reduce the recurrence and progression as effective as BCG instillation with lower adverse events.